Compare Digital Realty Trust, Inc. (DLR) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Digital Realty Trust, Inc. vs Incyte Corporation — how do they compare? Digital Realty Trust, Inc. trades at $176.26 (market cap $66.95B), while Incyte Corporation trades at $112.75 (market cap $22.99B). The key difference: Digital Realty Trust, Inc. is far larger — about 2.9× Incyte Corporation's market cap, and Digital Realty Trust, Inc. pays a 2.7% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Digital Realty Trust, Inc. for 94 Days and Incyte Corporation for 33 Days on average.
| DLR | INCY | |
|---|---|---|
Market Cap | $66.95B | $22.99B |
Volume | 1,766,660 | 1,274,487 |
Sector | Real Estate | Health |
52-Week High | $203.91 | $129.93 |
52-Week Low | $147.93 | $83.80 |
Typical Hold Time | 94 Days | 33 Days |
Enterprise Value | $85.67B | $18.50B |
Dividend Yield | 2.7% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DLR trades at $176.07, down 4.65% on the day, with a bearish technical signal from moving averages. The stock shows strong fundamental momentum, with Q2 2026 EPS beating expectations at $1.21 versus $0.4829, and revenue growth from $6.11B in 2025 to a projected $6.8B in 2026. Recent news highlights expansion in AI infrastructure, including a collaboration with Blackfuel and a new Los Angeles cable landing station, positioning the company to capitalize on data center demand.
The outlook for DLR is positive, driven by robust AI-driven demand and a record backlog, though high valuation multiples like a P/E of 88.03 pose a risk if growth slows. Analyst consensus is strongly bullish with a $222.35 price target, but investors face risks from significant capital expenditures and debt levels.
INCY trades at $112.75, up 0.02% on the day, with a bullish technical signal from oscillators but bearish moving averages. The company reported strong Q2 2026 earnings, beating expectations with EPS of $3.09 versus $2.15, and revenue growth from $5.14B in 2025 to a projected $5.8B in 2026. Recent FDA approval for Atebrioz and a strategic push for post-JAKAFI growth highlight pipeline progress. Valuation ratios appear reasonable with a P/E of 14.45 and EV/EBITDA of 8.94.
Outlook is positive with a consensus price target of $132.07, implying 17% upside, supported by 52% analyst buy ratings. Risks include reliance on JAKAFI, which loses exclusivity after 2029, and near-term earnings volatility as seen in the Q4 2025 miss. Strong cash flow and profitability metrics suggest resilience, but execution on pipeline diversification is critical for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Digital Realty Trust, Inc.
Digital Realty owns and operates nearly 300 data centers worldwide. It has more than 35 million rentable square feet across five continents. Digital's offerings range from retail co-location, where an enterprise may rent a single cabinet and rely on Digital to provide all the accommodations, to cold shells, where hyperscale cloud service providers can simply rent much, or all, of a barren, power-connected building. In recent years, Digital Realty has de-emphasized cold shells and now primarily provides higher-level service to tenants, which outsource their related IT needs to Digital. Digital Realty has also moved more into the co-location business, increasingly serving enterprises and facilitating network connections. Digital Realty operates as a real estate investment trust.
Read more on DLR →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
